186 related articles for article (PubMed ID: 21135175)
1. Ex vivo activity of histone deacetylase inhibitors against multidrug-resistant clinical isolates of Plasmodium falciparum and P. vivax.
Marfurt J; Chalfein F; Prayoga P; Wabiser F; Kenangalem E; Piera KA; Fairlie DP; Tjitra E; Anstey NM; Andrews KT; Price RN
Antimicrob Agents Chemother; 2011 Mar; 55(3):961-6. PubMed ID: 21135175
[TBL] [Abstract][Full Text] [Related]
2. Contrasting ex vivo efficacies of "reversed chloroquine" compounds in chloroquine-resistant Plasmodium falciparum and P. vivax isolates.
Wirjanata G; Sebayang BF; Chalfein F; Prayoga ; Handayuni I; Noviyanti R; Kenangalem E; Poespoprodjo JR; Burgess SJ; Peyton DH; Price RN; Marfurt J
Antimicrob Agents Chemother; 2015 Sep; 59(9):5721-6. PubMed ID: 26149984
[TBL] [Abstract][Full Text] [Related]
3. Comparative ex vivo activity of novel endoperoxides in multidrug-resistant plasmodium falciparum and P. vivax.
Marfurt J; Chalfein F; Prayoga P; Wabiser F; Wirjanata G; Sebayang B; Piera KA; Wittlin S; Haynes RK; Möhrle JJ; Anstey NM; Kenangalem E; Price RN
Antimicrob Agents Chemother; 2012 Oct; 56(10):5258-63. PubMed ID: 22850522
[TBL] [Abstract][Full Text] [Related]
4. Potent Ex Vivo Activity of Naphthoquine and Methylene Blue against Drug-Resistant Clinical Isolates of Plasmodium falciparum and Plasmodium vivax.
Wirjanata G; Sebayang BF; Chalfein F; Prayoga ; Handayuni I; Trianty L; Kenangalem E; Noviyanti R; Campo B; Poespoprodjo JR; Möhrle JJ; Price RN; Marfurt J
Antimicrob Agents Chemother; 2015 Oct; 59(10):6117-24. PubMed ID: 26195523
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of pyronaridine against multidrug-resistant Plasmodium falciparum and Plasmodium vivax.
Price RN; Marfurt J; Chalfein F; Kenangalem E; Piera KA; Tjitra E; Anstey NM; Russell B
Antimicrob Agents Chemother; 2010 Dec; 54(12):5146-50. PubMed ID: 20876370
[TBL] [Abstract][Full Text] [Related]
6. Profiling the anti-protozoal activity of anti-cancer HDAC inhibitors against Plasmodium and Trypanosoma parasites.
Engel JA; Jones AJ; Avery VM; Sumanadasa SD; Ng SS; Fairlie DP; Skinner-Adams T; Andrews KT
Int J Parasitol Drugs Drug Resist; 2015 Dec; 5(3):117-26. PubMed ID: 26199860
[TBL] [Abstract][Full Text] [Related]
7. Comparative gene expression profiling of P. falciparum malaria parasites exposed to three different histone deacetylase inhibitors.
Andrews KT; Gupta AP; Tran TN; Fairlie DP; Gobert GN; Bozdech Z
PLoS One; 2012; 7(2):e31847. PubMed ID: 22384084
[TBL] [Abstract][Full Text] [Related]
8. Measuring ex vivo drug susceptibility in Plasmodium vivax isolates from Cambodia.
Chaorattanakawee S; Lon C; Chann S; Thay KH; Kong N; You Y; Sundrakes S; Thamnurak C; Chattrakarn S; Praditpol C; Yingyuen K; Wojnarski M; Huy R; Spring MD; Walsh DS; Patel JC; Lin J; Juliano JJ; Lanteri CA; Saunders DL
Malar J; 2017 Sep; 16(1):392. PubMed ID: 28964258
[TBL] [Abstract][Full Text] [Related]
9. Ex vivo drug susceptibility of ferroquine against chloroquine-resistant isolates of Plasmodium falciparum and P. vivax.
Marfurt J; Chalfein F; Prayoga P; Wabiser F; Kenangalem E; Piera KA; Machunter B; Tjitra E; Anstey NM; Price RN
Antimicrob Agents Chemother; 2011 Sep; 55(9):4461-4. PubMed ID: 21730116
[TBL] [Abstract][Full Text] [Related]
10. Histone deacetylase inhibitors with high in vitro activities against Plasmodium falciparum isolates collected from Gabonese children and adults.
Koehne E; Kreidenweiss A; Zoleko Manego R; McCall M; Mombo-Ngoma G; Mackwitz MKW; Hansen FK; Held J
Sci Rep; 2019 Nov; 9(1):17336. PubMed ID: 31758015
[TBL] [Abstract][Full Text] [Related]
11. Determinants of in vitro drug susceptibility testing of Plasmodium vivax.
Russell B; Chalfein F; Prasetyorini B; Kenangalem E; Piera K; Suwanarusk R; Brockman A; Prayoga P; Sugiarto P; Cheng Q; Tjitra E; Anstey NM; Price RN
Antimicrob Agents Chemother; 2008 Mar; 52(3):1040-5. PubMed ID: 18180357
[TBL] [Abstract][Full Text] [Related]
12. Antimalarial activity of the anticancer histone deacetylase inhibitor SB939.
Sumanadasa SD; Goodman CD; Lucke AJ; Skinner-Adams T; Sahama I; Haque A; Do TA; McFadden GI; Fairlie DP; Andrews KT
Antimicrob Agents Chemother; 2012 Jul; 56(7):3849-56. PubMed ID: 22508312
[TBL] [Abstract][Full Text] [Related]
13. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
Negmeldin AT; Knoff JR; Pflum MKH
Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
[TBL] [Abstract][Full Text] [Related]
14. Structural Requirements of Histone Deacetylase Inhibitors: SAHA Analogs Modified on the Hydroxamic Acid.
Bieliauskas AV; Weerasinghe SV; Negmeldin AT; Pflum MK
Arch Pharm (Weinheim); 2016 May; 349(5):373-82. PubMed ID: 27062198
[TBL] [Abstract][Full Text] [Related]
15. Quantification of Plasmodium ex vivo drug susceptibility by flow cytometry.
Wirjanata G; Handayuni I; Prayoga P; Apriyanti D; Chalfein F; Sebayang BF; Kho S; Noviyanti R; Kenangalem E; Campo B; Poespoprodjo JR; Price RN; Marfurt J
Malar J; 2015 Oct; 14():417. PubMed ID: 26498665
[TBL] [Abstract][Full Text] [Related]
16. Antimalarial activity of phenylthiazolyl-bearing hydroxamate-based histone deacetylase inhibitors.
Dow GS; Chen Y; Andrews KT; Caridha D; Gerena L; Gettayacamin M; Johnson J; Li Q; Melendez V; Obaldia N; Tran TN; Kozikowski AP
Antimicrob Agents Chemother; 2008 Oct; 52(10):3467-77. PubMed ID: 18644969
[TBL] [Abstract][Full Text] [Related]
17. Lysine acetylation in sexual stage malaria parasites is a target for antimalarial small molecules.
Trenholme K; Marek L; Duffy S; Pradel G; Fisher G; Hansen FK; Skinner-Adams TS; Butterworth A; Ngwa CJ; Moecking J; Goodman CD; McFadden GI; Sumanadasa SD; Fairlie DP; Avery VM; Kurz T; Andrews KT
Antimicrob Agents Chemother; 2014 Jul; 58(7):3666-78. PubMed ID: 24733477
[TBL] [Abstract][Full Text] [Related]
18. Hydroxamic acid based histone deacetylase inhibitors with confirmed activity against the malaria parasite.
Giannini G; Battistuzzi G; Vignola D
Bioorg Med Chem Lett; 2015 Feb; 25(3):459-61. PubMed ID: 25563890
[TBL] [Abstract][Full Text] [Related]
19. Discovery of HDAC inhibitors with potent activity against multiple malaria parasite life cycle stages.
Hansen FK; Sumanadasa SD; Stenzel K; Duffy S; Meister S; Marek L; Schmetter R; Kuna K; Hamacher A; Mordmüller B; Kassack MU; Winzeler EA; Avery VM; Andrews KT; Kurz T
Eur J Med Chem; 2014 Jul; 82():204-13. PubMed ID: 24904967
[TBL] [Abstract][Full Text] [Related]
20. Potent antimalarial activity of histone deacetylase inhibitor analogues.
Andrews KT; Tran TN; Lucke AJ; Kahnberg P; Le GT; Boyle GM; Gardiner DL; Skinner-Adams TS; Fairlie DP
Antimicrob Agents Chemother; 2008 Apr; 52(4):1454-61. PubMed ID: 18212103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
